Canterbury DHB


Indications for IVIG usage

The haematological indications for prescribing IVIG can be classified as follows.

In This Section

Replacement Therapy

Therapeutic Treatment

Replacement Therapy

  1. Primary immunodeficiency.
  2. Myeloma and chronic lymphocyte leukaemia with severe secondary hypogammaglobulinaemia (IgG <5 g/L) and recurrent infections.
  3. Congenital or acquired humoral immunodeficiency syndrome with recurrent infections.

Therapeutic Treatment

  1. Idiopathic thrombocytopenic purpura (ITP) in adults or children at high risk of bleeding or prior to surgery to correct the platelet count.
  2. Kawasaki disease.
  3. Guillian Barre Syndrome.
  4. Chronic inflammatory demyelinating polyneuropathy.
  5. Pure red cell aplasia caused by parvovirus B19.
  6. Antenatal treatment of neonatal alloimmune thrombocytopenia, a maternal infusion, 1000 mg/kg/week from 20 weeks' gestation.

For further information, please see Criteria for the clinical use of intravenous immunoglobulin.

About this Canterbury DHB document (5144):

Document Owner:

Steve Gibbons (see Who's Who)

Last Reviewed:

June 2019

Next Review:

June 2022


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 5144